You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 1339 ALD2510: next generation Fc-enhanced, TREG-selective and IL-2-sparing anti-CD25 antibody with promising potential for the treatment of gynecological cancers

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1339 ALD2510: next generation Fc-enhanced, TREG-selective and IL-2-sparing anti-CD25 antibody with promising potential for the treatment of gynecological cancers

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Houacine J, Abes R, Marie-Cardine A, et al
1339 ALD2510: next generation Fc-enhanced, TREG-selective and IL-2-sparing anti-CD25 antibody with promising potential for the treatment of gynecological cancers
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.1339